The anti-angiogenic bevacizumab seems to potentiate dendritic cells’ functions, to facilitate CD8+ lymphocytes infiltration into tumor and to decrease Tregs functions, important studies such as the MODUL trial, cited above, and the BACCI trial (capecitabine in association with bevacizumab and atezolizumab in refractory mCRC) (45) were then developed, but both reported negative results in all the subgroups. This evidence concerns the gene CD8A and neoplasm.